In order to evaluate the molecular biology of the tumor cell population, a CTC (Circulating tumor cells) as well as a Cancer Stem Cells exam are important for both monitoring progress and determining prognosis. Yet, these tests are almost always missed by conventional oncologists.
By far, the most important test is this one because tumor circulatory stem cells can shed from a 2mm tumor and these are the cells that are the engins of metastases, from which most cancer patients die.
The best test on the market is the Cell Search Circulating Tumor Cell (CTC) test. This test is a simple blood test. Some conventional ontologists use this test in assessing the prognosis of patients with metastatic breast, colorectal, or prostate cancer. But most integrative and holistic oncologists will use this test for many more cancers and indications.
The CellSearch System identifies and enumerates the number of circulating tumor cells (CTCs) in a blood specimen.(1) Studies suggest that the number of CTCs is associated with progression-free and overall survival in patients with metastatic colorectal cancer.(2,3)
Results are reported as favorable or unfavorable. In patients with metastatic colon cancer, the finding of > or =3 circulating tumor cells/7.5 mL of blood is predictive of shorter progression-free survival and overall survival.(2)
This test is FDA approved only for monitoring colon, prostate and breat cancer patients with metastatic disease. Blood specimens must be drawn into a CellSave tube and be processed in the laboratory within 96 hours of draw. (4)
This test does not provide information about the primary site of a tumor. It measures the risk as well as the density of metastases. The CellSearch test is the only FDA-approved test for CTC assessment. Each result of the CellSearch test is verified by both a cytotechnologist and a pathologist to ensure quality.
Currently, Medicare and some private insurers cover the CellSearch test, which costs about $350